Search Clinical Trials

6 Results

Not Yet Recruiting
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants (External Link)
The objective of this research protocol is to assess the impacts of genomic sequencing in healthy infants from ethnically and racially diverse communities as part of routine pediatric care. Investigators …
Baylor Role: Collaborator
Not Yet Recruiting
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708 (External Link)
This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. Evaluations will include family …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair (External Link)
The eligibility of the patient to participate in this study will be determined by the Investigator on the basis of the inclusion and exclusion criteria. Consent will be obtained from …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (External Link)
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Not Yet Recruiting
Clear Aligners for the Treatment of Dental Malocclusion in OI Types III and IV (External Link)
Osteogenesis imperfecta (OI) is a heritable connective tissue disorder leading to frequent fractures and bone deformities. In about 90% of individuals with OI, the disease is caused by dominant mutations …
Baylor Role: Lead Sponsor
Not Yet Recruiting
TCR Alpha/Beta and CD19 TCD in HCT for Patients With Hematological Malignancies and Nonmalignant Disorders (External Link)
This is a single arm pilot study of haploidentical HCT (HHCT) with ex vivo TCRαβ+ and CD19+ depletion using the CliniMACS device in patients with hematological malignancies and non-malignant disorders. …
Baylor Role: Lead Sponsor